By injecting Dab2 mRNA encapsulated in lipid nanoparticles (LNPs), or using the FOXM1 inhibitor FDI-6, wound healing was significantly enhanced through increased angiogenesis, which could lay the foundation for the development of novel therapies to enhance angiogenesis in diabetes. Here, FOXM1 is linked to diabetes mellitus.